The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China

BACKGROUND: Multiple myeloma is genetically heterogeneous, and chromosome abnormalities play a pivotal role in prognosis. A gain in chromosome 1q (+1q) is among the most common cytogenetic abnormalities; however, its relationship with overall survival (OS) and progression-free survival (PFS) in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qingxiao, Han, Xiaoyan, Zheng, Gaofeng, Yang, Yang, Li, Yi, Zhang, Enfan, Yang, Li, Dong, Mengmeng, He, Donghua, He, Jingsong, Cai, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808074/
https://www.ncbi.nlm.nih.gov/pubmed/36605445
http://dx.doi.org/10.3389/fonc.2022.1084683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808074/
https://www.ncbi.nlm.nih.gov/pubmed/36605445
http://dx.doi.org/10.3389/fonc.2022.1084683

Ejemplares similares